About Us

  Barry has over 20 years business development experience much of it in the personalised medicine space. He recently spent 3 years in Boston, MA with InvestNI to investigate technology opportunities and further developed  his professional network across the US within the biotech and pharma sector. He brings a wealth of relevant experience, having previously held roles in biomedical research, sales & marketing within the biotech sector, and innovation management with Ulster University. As the Principal at Marlborough Bioconsulting, he has worked in a business development capacity for several biotechs including Lantern Pharma Inc and Biological Mimetics Inc. He also led the team that founded the Clinical Translational Research and Innovation Centre (C-TRIC) in NI, a not for profit company, which he managed and for whom he acted as Company Secretary. 

Dr.Tobin has led research and technical programs at Biological Mimetics Inc since 1999.  A molecular biologist, Dr. Tobin has significant experience in project direction and management; design, planning, and execution of research projects; and coordination of multi-site studies. Dr Tobin has a strong interest in precision medicine having previously worked at the National Cancer Institute, where he led several projects to understand the molecular mechanisms of cancer and rationally design small molecule inhibitors. Dr.Tobin also has founded and co-founded several successful biotechsincluding Lantern Pharma, an AI-directed precision oncology company which recently raised $95m via IPO; Keystone Bio, an antibody therapeutic company; and Rapid Molecular Diagnostics, Inc., formed to develop high-throughput diagnostics based on rapid ellipsometry outputs.

Susan has helped build some of Massachusetts top successful Biotechnology companies from the ground up as a member of the founding Executive Teams of Moderna, Momenta Pharmaceuticals and Cubist Pharmaceuticals.  She played key roles in managing these companies to grow from the “big science idea” through seed and follow-on venture funding, scientific proof of concept, IPOs, clinical development and the achievement of multiple FDA drug approvals.